The Trailhead evaluation data highlights improvements in key physical markers, specifically reduced fat infiltration, better upper-limb performance, and increased handgrip strength. Perry Shieh, a professor at the UCLA David Geffen School of Medicine, noted that the consistency across safety and strength metrics offers a promising outlook for the candidate’s future clinical path.
In section Market Quotes
Satellos Bioscience Stock Surges on Duchenne Drug Trial Data
Shares of Satellos Bioscience climbed 16% to $9.49 following positive clinical results for SAT-3247, an experimental treatment for Duchenne muscular dystrophy. The company’s stock has now gained 61% since January, reflecting growing investor confidence in its approach to degenerative muscle disease therapy.
Chief Executive Frank Gleeson confirmed these findings bolster the ongoing Basecamp study, a phase 2 trial for the same drug. The company expects to finalize patient enrollment for that study by the end of the third quarter.
Comments (0)
No comments yet. Be the first!